Aerpio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

NEXT STORY
Aeterna Zentaris Continues to Demonstrate Pipeline Expansion – Announces the Initiation of Its Preclinical Program for the Potential Treatment of Primary Hypoparathyroidism
PREV STORY
Acerus Reports Fourth Quarter and Full Year 2020 Financial Results
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Aerpio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

NEXT STORY
Aeterna Zentaris Continues to Demonstrate Pipeline Expansion – Announces the Initiation of Its Preclinical Program for the Potential Treatment of Primary Hypoparathyroidism
PREV STORY
Acerus Reports Fourth Quarter and Full Year 2020 Financial Results
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

OSE Immunotherapeutics to Present New Clinical and Preclinical Data on its Immuno-Oncology Portfolio at AACR 2019

author_avatar
NASDAQ Market News

Novadip Biosciences announces EUR 19 million Series B financing backed by international investors

author_avatar
NASDAQ Market News

Continued strong Cresemba® (isavuconazole) sales trigger milestone from Pfizer to Basilea of USD 10 million

author_avatar
NASDAQ Market News